![]() |
½ÃÀ庸°í¼
»óǰÄÚµå
1542871
¼¼°èÀÇ À¯¹æ º´º¯ À§Ä¡°áÁ¤ ½ÃÀå(2024-2031³â)Global Breast Lesion Localization Methods Market - 2024-2031 |
°³¿ä
¼¼°èÀÇ À¯¹æ º´º¯ À§Ä¡°áÁ¤½ÃÀåÀº 2023³â¿¡ 3¾ï 6,387¸¸ ´Þ·¯¿¡ ´ÞÇϸç, 2031³â¿¡´Â 7¾ï 9,515¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, ¿¹Ãø ±â°£ÀÎ 2024-2031³â CAGRÀº 10.5%·Î ¼ºÀåÇÒ Àü¸ÁÀÔ´Ï´Ù.
À¯¹æ º´º¯ À§Ä¡°áÁ¤ ¹æ¹ýÀº ¼ö¼ú Àü ½Ã¼ú·Î, ¹æ»ç¼ºµ¿À§¿ø¼Ò, ÀÚ±â ÃßÀûÀÚ, ¿ÍÀÌ¾î µî ±¹¼ÒÈ Àåºñ¸¦ ¾Ï °ËÃâ ºÎÀ§¿¡ »ðÀÔÇÏ¿© ¿Ü°úÀû ÀýÁ¦½Ã ºñÃËÁö º´º¯À» ±¹¼ÒÈÇÏ¿© ¼ö¼ú½Ã º´º¯À» ±¹¼ÒȽÃŰ´Â ¹æ¹ýÀÔ´Ï´Ù.
À¯¹æ º´º¯ À§Ä¡°áÁ¤ ¼ö¼úÀº º´º¯ÀÇ À¯Çü°ú À§Ä¡¿¡ µû¶ó ÃÊÀ½ÆÄ, ÀÚ±â°ø¸í¿µ»ó(MRI), À¯¹æÃÔ¿µ¼ú µîÀÇ ¼ö¼ú À¯µµ ½Ã½ºÅÛÀ» ÀÌ¿ëÇÏ¿© ½ÃÇàµË´Ï´Ù. À¯¹æ º´º¯ÀÇ Á¶±â ¹ß°ß°ú ÇÔ²² Ç¥Àû º´º¯ÀÇ Á¤È®ÇÑ ÀýÁ¦¸¦ º¸ÀåÇϱâ À§ÇØ À¯¼±Á¾±« ÀýÁ¦¼ú ¹× ¿Ü°úÀû »ý°Ë¼úÀÇ 50%±îÁö ±¹¼ÒȹýÀÌ ÇÊ¿äÇÏ°Ô µÇ¾ú½À´Ï´Ù.
ÃËÁø¿äÀΰú ¾ïÁ¦¿äÀÎ
À¯¹æ¾Ï ¹ßº´·ü Áõ°¡
¿©¼ºÀÇ À¯¹æ¾Ï ¹ßº´·ü Áõ°¡´Â À¯¹æ º´º¯ À§Ä¡°áÁ¤ ¹æ¹ý ¼¼°è ½ÃÀåÀ» ÃËÁøÇÏ´Â ÁÖ¿ä ¿äÀÎÀÔ´Ï´Ù. ±¹¼ÒÈ ´Ü°è¸¦ ÅëÇØ ¿Ü°ú ÀÇ»ç´Â ¼ö¼ú Áß º´º¯À» Á¤È®ÇÏ°Ô ½Äº°Çϰí Á¦°ÅÇÒ ¼ö ÀÖ½À´Ï´Ù.
¿¹¸¦ µé¾î ¼¼°è ¾Ï ¿¬±¸ ±â±Ý¿¡ µû¸£¸é 2022³â ¿©¼º À¯¹æ¾Ï ½Å±Ô ¹ßº´ °Ç¼ö´Â 229¸¸ 6840°ÇÀ̾ú´Ù°í ÇÕ´Ï´Ù.
¸ðµç ±¹°¡¿¡´Â ¼ö¸¹Àº À¯¹æ¾Ï ȯÀÚ°¡ ÀÖÀ¸¸ç, ±¹¼ÒÀû Çʿ伺ÀÌ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î Áß±¹¿¡¼´Â 357,161¸í ÀÌ»óÀÌ À¯¹æ¾Ï¿¡ °É·È°í, ¹Ì±¹¿¡¼´Â 274,375¸íÀÌ À¯¹æ¾Ï¿¡ °É·È½À´Ï´Ù. µû¶ó¼ À¯¹æ¾Ï ȯÀÚ Áõ°¡´Â ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÒ ¼ö ÀÖ½À´Ï´Ù.
÷´Ü ±â¼úÀÇ °íºñ¿ë
¹æ»ç¼º Á¾ÀÚ ÇöÁöÈ(RSL) ¹× ÀÚ±â Á¾ÀÚ ÇöÁöÈ(MSL)¿Í °°Àº ÷´Ü ÇöÁöÈ Á¢±Ù¹ýÀº Á¾Á¾ °í°¡ÀÇ Æ¯¼ö Àåºñ¸¦ »ç¿ëÇØ¾ß ÇÕ´Ï´Ù. ÀÌ·¯ÇÑ ±â¼úÀº Ãʱâ ÅõÀÚ»Ó¸¸ ¾Æ´Ï¶ó Áö¼ÓÀûÀÎ À¯Áöº¸¼ö, Ư¼ö Àåºñ ¹× Àç·á°¡ ÇÊ¿äÇÒ ¼ö ÀÖÀ¸¸ç, ÀÌ·Î ÀÎÇØ Àüü ºñ¿ëÀÌ Áõ°¡ÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ´Â ÀÇ·á ¼ºñ½º ÇÁ·Î¹ÙÀÌ´õ¿¡°Ô °æÁ¦Àû ºÎ´ãÀ» ÁÙ ¼ö ÀÖ½À´Ï´Ù.
½ÃÀå ºÎ¹® ºÐ¼®
¼¼°è À¯¹æ º´º¯ À§Ä¡°áÁ¤ ¹æ¹ý ½ÃÀåÀº ¹æ¹ý, ±â±â, Áö¿ªº°·Î ¼¼ºÐȵ˴ϴÙ.
¿ÍÀÌ¾î °¡À̵å ÇϺΠÇöÁöÈ(WGL) ºÎ¹®ÀÌ ½ÃÀå Á¡À¯À²À» µ¶Á¡ÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
À¯¼± °¡À̵å ÇÏÀÇ ·ÎÄöóÀÌÁ¦À̼ÇÀº °¡Àå Å« Á¡À¯À²À» Â÷ÁöÇÏ¸ç ¿¹Ãø ±â°£ Áß ¿ìÀ§¸¦ À¯ÁöÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ±× ÀÌÀ¯´Â Á¶±â Á¤Âø°ú ÃÖÁ¾»ç¿ëÀÚµé »çÀÌ¿¡¼ ³ôÀº äÅ÷ü¿¡ ±âÀÎÇÕ´Ï´Ù. ÀÌ·¯ÇÑ ÇöÁöȸ¦ ÅëÇØ º´º¯ÀÇ Á¤È®ÇÑ À§Ä¡ ÆÄ¾ÇÀÌ °¡´ÉÇϸç, ƯÈ÷ ¹Ì¼¼ÇÑ º´º¯À̳ª ´Ù¸¥ ¹æ¹ýÀ¸·Î´Â µµ¸éÀÌ ¾î·Á¿î º´º¯À» µµ¸éÈÇÒ ¼ö ÀÖ½À´Ï´Ù.
¿ÍÀÌ¾î °¡À̵å ÇÏ ±¹¼ÒÈ´Â À¯¹æ ¼ö¼úÀÇ Áö½Ã ¹æ¹ýÀ¸·Î È®¸³µÇ°í ÀϹÝÀûÀ¸·Î »ç¿ëµÇ´Â ¹æ¹ýÀÌ¸ç ¿À·£ ¼º°øÀÇ ¿ª»ç¸¦ °¡Áö°í ÀÖ½À´Ï´Ù. ÀÌ ½Ã¼úÀº Àß ±ÔÁ¦µÇ¾î ÀÖ°í, ³ôÀº ¾ÈÀü¼º°ú À¯È¿¼º ÇÁ·ÎÆÄÀÏÀ» °¡Áö°í ÀÖÀ¸¸ç, Áö¼ÓÀûÀÎ »ç¿ë°ú äÅÃÀ» °¡´ÉÇÏ°Ô ÇÕ´Ï´Ù. µû¶ó¼ À§ÀÇ ¿äÀεéÀÌ ÀÌ ºÎ¹® ½ÃÀå Á¡À¯À²À» À¯ÁöÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
½ÃÀå Áö¿ªº° Á¡À¯À²
ºÏ¹Ì´Â À¯¹æ º´º¯ À§Ä¡°áÁ¤¹ý ½ÃÀå Á¡À¯À²¿¡¼ Áß¿äÇÑ À§Ä¡¸¦ Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
ºÏ¹Ì´Â Àü ¼¼°è À¯¹æ º´º¯ À§Ä¡°áÁ¤¹ý ½ÃÀå¿¡¼ Å« Á¡À¯À²À» Â÷ÁöÇϰí ÀÖÀ¸¸ç, ±× ÁÖ¿ä ¿äÀÎÀº ÀÌ Áö¿ªÀÇ ³ôÀº À¯¹æ¾Ï À¯º´·üÀÔ´Ï´Ù. ÀÌ Áö¿ª¿¡´Â ±¤¹üÀ§ÇÑ È¯ÀÚÃþÀÌ Á¸ÀçÇϸç, Áß¿äÇÑ ÀÇ·á ±â¾÷µµ Á¸ÀçÇÕ´Ï´Ù.
¶ÇÇÑ ¹Ì±¹ µî ½ÅÈï ½ÃÀå¿¡¼ÀÇ ³ôÀº ÀÎÁöµµ, ³ôÀº ÀÇ·áºñ, ¿¬±¸½Ã¼³ ¹× ¿¬±¸¼ÒÀÇ Á¸Àç, ÀÌ Áö¿ªÀÇ ÁÖ¿ä ±â¾÷ÀÇ ±¤¹üÀ§ÇÑ Á¶»ç Ȱµ¿, ÷´Ü ÀÇ·á±â¼úÀÇ Á¶±â µµÀÔ µîÀÌ ÀÌ Áö¿ª ½ÃÀåÀÇ ¿øµ¿·ÂÀÌ µÇ°í ÀÖ½À´Ï´Ù.
¿¹¸¦ µé¾î 2022³â ¹Ì±¹ Áúº´¿¹¹æÅëÁ¦¼¾ÅÍÀÇ º¸°í¿¡ µû¸£¸é 2021³â¿¡´Â 272,454¸íÀÇ À¯¹æ¾Ï ȯÀÚ°¡ »õ·Î ¹ß»ýÇß°í, 2022³â¿¡´Â 42,211¸íÀÇ ¿©¼ºÀÌ À¯¹æ¾ÏÀ¸·Î »ç¸ÁÇß½À´Ï´Ù.
¶ÇÇÑ ¹Ì±¹¾ÏÇùȸ(American Cancer Society, Inc.)¿¡ µû¸£¸é 2024³â¿¡´Â ¿©¼º¿¡¼ ¾à 310,720°ÇÀÇ Ä§À±¼º À¯¹æ¾ÏÀÌ »õ·Î Áø´ÜµÉ °ÍÀ¸·Î ¿¹»óµÇ¸ç, ¾à 56,500°ÇÀÇ À¯°ü¾Ï(DCIS)ÀÌ »õ·Î Áø´ÜµÉ °ÍÀ¸·Î Ãß»êµË´Ï´Ù. ÀÌ·¯ÇÑ À¯¹æ¾Ï ȯÀÚ Áõ°¡´Â ±¹¼ÒÈ ¹æ¹ý¿¡ ´ëÇÑ ¼ö¿ä¸¦ Áõ°¡½Ãų °ÍÀ¸·Î ¿¹»óµÇ¸ç, ÀÌ ºÐ¾ß´Â Áö¹èÀûÀÎ À§Ä¡¸¦ Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
Overview
Global Breast Lesion Localization Market reached US$ 363.87 million in 2023 and is expected to reach US$ 795.15 million by 2031, growing at a CAGR of 10.5% during the forecast period 2024-2031.
Breast lesion localization methods are pre-surgical procedures, where localization devices such as radioisotopes, magnetic tracers, and wires are inserted into cancer-detected sites to localize a non-palpable lesion at the time of surgical excision.
Breast Lesion Localization Methods procedure is carried out using surgical guidance systems such as ultrasound, Magnetic Resonance Imaging (MRI), or mammography, depending on the type of lesion and its location. With earlier detection of breast lesions, localization procedures have become necessary in up to 50% of all lumpectomy and surgical biopsy procedures to ensure accurate removal of the target lesion.
Market Dynamics: Drivers & Restraints
Increasing incidence of breast cancer
The increasing incidences of breast cancer among women are the predominant driving factor of the global market for breast lesion localization methods. The localization step ensures that the surgeon can accurately identify and excise the lesion during the surgery.
For instance, according to the World Cancer Research Fund International, it is stated that there were 2,296,840 new cases of breast cancer in 2022 among women.
Every country contains a large number of breast cancer patients which is raising the need for localization. For instance, China accounts for over 357,161 individuals suffering from breast cancer and the U.S. accounts for almost 274, 375 individuals with breast cancer. Thus, the increasing number of individuals with breast cancer could raise the market growth.
High cost of advanced technologies
Advanced localization approaches, such as radioactive seed localization (RSL) and magnetic seed localization (MSL), often require the use of costly specialized equipment. Beyond the initial investment, these technologies may necessitate ongoing maintenance, specialized equipment, and materials, which increases the entire cost. This may cause a financial burden on healthcare providers.
Market Segment Analysis
The global breast lesion localization market is segmented based on method, devices and region.
Wire-Guided Localization (WGL) segment is expected to dominate the market share
The wire-guided localization share holds the most significant market share and is expected to remain dominant over the forecast period. It can be attributed to its early establishment and higher adoption rate among end-users. This localization provides precise localization of lesions, especially lesions that are tiny or difficult to visualize using other methods.
Wire-guided localization is a well-established and commonly used approach for directing breast surgery, with a long history of success. The procedure is well-regulated and has a high safety and efficacy profile, which helps to ensure its continued use and adoption. Thus, the above factors are expected to hold the segment in the market share.
Market Geographical Share
North America is expected to hold a significant position in the breast lesion localization market share
North America holds a substantial share of the global breast lesion localization methods market, and it is primarily attributed to factors such as the high prevalence of breast cancer in the region. It has a broad base of the patient population and the presence of significant medical companies.
Moreover, the higher awareness in developed areas such as the U.S., high healthcare expenditure, the presence of research facilities and labs, the extensive research activities undertaken by a majority of prominent players in the area, and the early adoption of advanced medical technologies help propel the regional market.
For instance, according to the Centers for Disease Control and Prevention report in 2022, 272,454 new breast cancers were reported in females in 2021, and in 2022, 42,211 females died from breast cancer.
Additionally, according to the American Cancer Society, Inc., it is estimated that about 310,720 new cases of invasive breast cancer will be diagnosed in women in 2024, and about 56,500 new cases of ductal carcinoma in situ (DCIS) will be diagnosed. Thus, the increasing number of breast cancer cases is expected to increase the demand for localization methods, thus holding the region in the dominant position.
Wire-Guided Localization (WGL)
Magnetic Tracers
Electromagnetic Reflectors
Radio Guided Occult-Lesion Localization (ROLL)
Radioactive-Seed Localization (RSL)
Others
Breast Biopsy Marker Localization
Others
Radioactive Seeds
Radar Reflectors
Magnetic Seeds
Radiofrequency Identification Tag Localizers (RFIDs)
Wires
Coils
Others
North America
The U.S.
Canada
Mexico
Europe
Germany
UK
France
Italy
Spain
Rest of Europe
South America
Brazil
Argentina
Rest of South America
Asia-Pacific
China
India
Japan
South Korea
Rest of Asia-Pacific
Middle East and Africa
Market Competitive Landscape
The major global players in the market include Becton, Dickinson, and Company, Sterylab S.r.l., SOMATEX Medical Technologies GmbH, Argon Medical Devices, Hologic Inc., Cook Medical, Mammotome, Merit Medical Systems, Inc., Theragenics Corporation and Mermaid Medical among others.
To visualize the global breast lesion localization market segmentation based on type, drug type, route of administration, distribution channel, and region as well as understand key commercial assets and players.
Identify commercial opportunities by analyzing trends and co-development.
Excel data sheet with numerous data points of breast lesion localization market-level with all segments.
PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
Product mapping available as Excel consisting of key products of all the major players.
The global breast lesion localization market report would provide approximately 53 tables, 47 figures, and 176 pages.
Target Audience 2024
Manufacturers/ Buyers
Industry Investors/Investment Bankers
Research Professionals
Emerging Companies